Search

Your search keyword '"Bhoj, Vijay"' showing total 204 results
Start Over Author "Bhoj, Vijay"
204 results on '"Bhoj, Vijay"'

1. Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders

Author

Baglaenko, Yuriy, Wagner, Catriona, Bhoj, Vijay G, Brodin, Petter, Gershwin, M Eric, Graham, Daniel, Invernizzi, Pietro, Kidd, Kenneth K, Korsunsky, Ilya, Levy, Michael, Mammen, Andrew L, Nizet, Victor, Ramirez-Valle, Francisco, Stites, Edward C, Williams, Marc S, Wilson, Michael, Rose, Noel R, Ladd, Virginia, and Sirota, Marina

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Autoimmune Disease, Biotechnology, Human Genome, Brain Disorders, Prevention, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system, Generic health relevance, Good Health and Well Being, Autoimmunity, bioinformatics, data integration, diagnosis, genomics
Abstract

Precision Medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. Autoimmune diseases are those in which the body's natural defense system loses discriminating power between its own cells and foreign cells, causing the body to mistakenly attack healthy tissues. These conditions are very heterogeneous in their presentation and therefore difficult to diagnose and treat. Achieving precision medicine in autoimmune diseases has been challenging due to the complex etiologies of these conditions, involving an interplay between genetic, epigenetic, and environmental factors. However, recent technological and computational advances in molecular profiling have helped identify patient subtypes and molecular pathways which can be used to improve diagnostics and therapeutics. This review discusses the current understanding of the disease mechanisms, heterogeneity, and pathogenic autoantigens in autoimmune diseases gained from genomic and transcriptomic studies and highlights how these findings can be applied to better understand disease heterogeneity in the context of disease diagnostics and therapeutics.

Published
2023

2. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

Author

Parker, Kevin R, Migliorini, Denis, Perkey, Eric, Yost, Kathryn E, Bhaduri, Aparna, Bagga, Puneet, Haris, Mohammad, Wilson, Neil E, Liu, Fang, Gabunia, Khatuna, Scholler, John, Montine, Thomas J, Bhoj, Vijay G, Reddy, Ravinder, Mohan, Suyash, Maillard, Ivan, Kriegstein, Arnold R, June, Carl H, Chang, Howard Y, Posey, Avery D, and Satpathy, Ansuman T

Subjects
Biomedical and Clinical Sciences, Immunology, Immunization, Neurosciences, Vaccine Related, Rare Diseases, Biotechnology, Genetics, Aetiology, 2.1 Biological and endogenous factors, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Neurological, Animals, Antibodies, Bispecific, Antigens, CD19, B-Lymphocytes, Blood-Brain Barrier, Brain, Cell Line, Tumor, Cytotoxicity, Immunologic, Epithelial Cells, Humans, Immunotherapy, Immunotherapy, Adoptive, Mice, Mice, Inbred NOD, Mice, SCID, Muscle, Smooth, Vascular, Neoplasms, Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen, Single-Cell Analysis, T-Lymphocytes, Xenograft Model Antitumor Assays, Biological Sciences, Medical and Health Sciences, Developmental Biology, Biological sciences, Biomedical and clinical sciences
Abstract

CD19-directed immunotherapies are clinically effective for treating B cell malignancies but also cause a high incidence of neurotoxicity. A subset of patients treated with chimeric antigen receptor (CAR) T cells or bispecific T cell engager (BiTE) antibodies display severe neurotoxicity, including fatal cerebral edema associated with T cell infiltration into the brain. Here, we report that mural cells, which surround the endothelium and are critical for blood-brain-barrier integrity, express CD19. We identify CD19 expression in brain mural cells using single-cell RNA sequencing data and confirm perivascular staining at the protein level. CD19 expression in the brain begins early in development alongside the emergence of mural cell lineages and persists throughout adulthood across brain regions. Mouse mural cells demonstrate lower levels of Cd19 expression, suggesting limitations in preclinical animal models of neurotoxicity. These data suggest an on-target mechanism for neurotoxicity in CD19-directed therapies and highlight the utility of human single-cell atlases for designing immunotherapies.

Published
2020

3. Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy

Author

Uribe-Herranz, Mireia, Beghi, Silvia, Ruella, Marco, Parvathaneni, Kalpana, Salaris, Silvano, Kostopoulos, Nektarios, George, Subin S., Pierini, Stefano, Krimitza, Elisavet, Costabile, Francesca, Ghilardi, Guido, Amelsberg, Kimberly V., Lee, Yong Gu, Pajarillo, Raymone, Markmann, Caroline, McGettigan-Croce, Bevin, Agarwal, Divyansh, Frey, Noelle, Lacey, Simon F., Scholler, John, Gabunia, Khatuna, Wu, Gary, Chong, Elise, Porter, David L., June, Carl H., Schuster, Stephen J., Bhoj, Vijay, and Facciabene, Andrea

Published
2023
Full Text
View/download PDF

7. Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab

Author

Lee, Kyumin, Chau, Julia Q., Suber, Yani B., Sternberg, Anna R., Pishko, Allyson M., George, Lindsey A., Bhoj, Vijay G., Doshi, Bhavya S., and Samelson-Jones, Benjamin J.

Abstract

Emicizumab improves the procoagulant activity of select loss-of-function factor IX (FIX) variants with likely dysfunctional assembly of the intrinsic Xase complex, resulting in hemophilia B (HB). FVIII mimetics may represent an alternative nonfactor therapy for select patients with HB.

Published
2024
Full Text
View/download PDF

8. Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis

Author

Mack, Ethan Andrew, primary, Dougher, Meaghan C., additional, Ginda, Ashley, additional, Cahill, Caitlin Q, additional, Murter, Melissa, additional, Schell, Kevin, additional, Tanhehco, Yvette C, additional, Bhoj, Vijay, additional, Fesnak, Andrew D, additional, Siegel, Don L, additional, Kambayashi, Taku, additional, Aqui, Nicole, additional, and O'Doherty, Una, additional

Published
2023
Full Text
View/download PDF

9. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies

Author

Zhang, Zheng, primary, Markmann, Caroline, additional, Yu, Ming, additional, Agarwal, Divyansh, additional, Rostami, Susan, additional, Wang, Wei, additional, Liu, Chengyang, additional, Zhao, Huiwu, additional, Ochoa, Trini, additional, Parvathaneni, Kalpana, additional, Xu, Xiaoming, additional, Li, Eric, additional, Gonzalez, Vanessa, additional, Khadka, Roman, additional, Hoffmann, Jennifer, additional, Knox, James J., additional, Scholler, John, additional, Marcellus, Brooke, additional, Allman, David, additional, Fraietta, Joseph A., additional, Samelson-Jones, Benjamin, additional, Milone, Michael C., additional, Monos, Dimitri, additional, Garfall, Alfred L., additional, Naji, Ali, additional, and Bhoj, Vijay G., additional

Published
2023
Full Text
View/download PDF

10. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

Author

Pillai, Vinodh, Muralidharan, Kavitha, Meng, Wenzhao, Bagashev, Asen, Oldridge, Derek A., Rosenthal, Jaclyn, Van Arnam, John, Melenhorst, Jos J., Mohan, Diwakar, DiNofia, Amanda M., Luo, Minjie, Cherian, Sindhu, Fromm, Jonathan R., Wertheim, Gerald, Thomas-Tikhonenko, Andrei, Paessler, Michele, June, Carl H., Luning Prak, Eline T., Bhoj, Vijay G., Grupp, Stephan A., Maude, Shannon L., and Rheingold, Susan R.

Published
2019
Full Text
View/download PDF

14. Adaptation of HLA testing to characterize the cynomolgus macaque MHC polymorphisms and alloantibody signatures.

Author

Agarwal, Divyansh, Liu, Chengyang, Bhoj, Vijay, Kearns, Jane, Bharani, Tina, Choe, Insuk, Vivek, Kumar, O'Connor, David H., Wiseman, Roger W., Duquesnoy, René J., Naji, Ali, and Kamoun, Malek

Subjects
MAJOR histocompatibility complex, MONOCLONAL antibodies, MACAQUES, T cells, DNA copy number variations, ANIMAL welfare, HLA histocompatibility antigens, HUMAN genetics
Abstract

Nonhuman primates are the closest animal models to humans with respect to genetics and physiology. Consequently, a critical component of immunogenetics research relies on drawing inferences from the cynomolgus macaque to inform human trials. Despite the conserved organization of the Major Histocompatibility Complex (MHC) between cynomolgus macaques and humans, MHC genotyping of cynomolgus macaques is challenging due to high rates of copy number variants, duplications, and rearrangements, particularly at the MHC class I loci. Furthermore, the limited availability of commercial reagents specific to cynomolgus macaques that can be used to characterize anti‐MHC class I and class II antibody (Ab) specificities in cynomolgus macaques presents a major bottleneck in translational research. Here we successfully characterized cynomolgus macaque Mafa class I and class II serologic specificities in 86 animals originating from various geographical regions using the complement dependent cytotoxicity (CDC) assay with human HLA class I and class II monoclonal antibody (mAb) typing trays. Further, we successfully induced and characterized anti‐Mafa class I and class II alloantibody specificity using HLA single antigen bead assays. We also subsequently tracked the alloAb burden in the animals during treatment with anti‐B lymphocyte stimulator (BLyS) treatment. Altogether, these methods can be easily used in translational research to serotype MHC class I and class II specificity in macaques, characterize their alloAb specificity, and evaluate the efficacy of novel therapeutic modalities in depleting circulating alloAbs in these animals. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia

Author

Kong, Weimin, Dimitri, Alexander, Wang, Wenliang, Jung, In-Young, Ott, Christopher J., Fasolino, Maria, Wang, Yan, Kulikovskaya, Irina, Gupta, Minnal, Yoder, Todd, DeNizio, Jamie E., Everett, John K., Williams, Erik F., Xu, Jun, Scholler, John, Reich, Tyler J., Bhoj, Vijay G., Haines, Kathleen M., Maus, Marcela V., Melenhorst, J. Joseph, Young, Regina M., Jadlowsky, Julie K., Marcucci, Katherine T., Bradner, James E., Levine, Bruce L., Porter, David L., Bushman, Frederic D., Kohli, Rahul M., June, Carl H., Davis, Megan M., Lacey, Simon F., Vahedi, Golnaz, and Fraietta, Joseph A.

Subjects
T cells -- Receptors, Polypeptides -- Health aspects, Antigen receptors, T cell -- Genetic aspects -- Health aspects, Cellular therapy -- Methods, Immunotherapy -- Methods, Chronic lymphocytic leukemia -- Care and treatment, Health care industry
Abstract

Chimeric antigen receptor (CAR) T cells have induced remarkable antitumor responses in B cell malignancies. Some patients do not respond because of T cell deficiencies that hamper the expansion, persistence, and effector function of these cells. We used longitudinal immune profiling to identify phenotypic and pharmacodynamic changes in CD19-directed CAR T cells in patients with chronic lymphocytic leukemia (CLL). CAR expression maintenance was also investigated because this can affect response durability. CAR T cell failure was accompanied by preexisting T cell-intrinsic defects or dysfunction acquired after infusion. In a small subset of patients, CAR silencing was observed coincident with leukemia relapse. Using a small molecule inhibitor, we demonstrated that the bromodomain and extra-terminal (BET) family of chromatin adapters plays a role in downregulating CAR expression. BET protein blockade also ameliorated CAR T cell exhaustion as manifested by inhibitory receptor reduction, enhanced metabolic fitness, increased proliferative capacity, and enriched transcriptomic signatures of T cell reinvigoration. BET inhibition decreased levels of the TET2 methylcytosine dioxygenase, and forced expression of the TET2 catalytic domain eliminated the potency-enhancing effects of BET protein targeting in CAR T cells, providing a mechanism linking BET proteins and T cell dysfunction. Thus, modulating BET epigenetic readers may improve the efficacy of cell-based immunotherapies., Introduction The adoptive transfer of autologous CD19-targeted chimeric antigen receptor (CAR) T cells has shown remarkable activity in patients with B cell malignancies (1-3). Upon treatment with a CAR signaling [...]

Published
2021
Full Text
View/download PDF

16. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Author

Ruella, Marco, Xu, Jun, Barrett, David M., Fraietta, Joseph A., Reich, Tyler J., Ambrose, David E., Klichinsky, Michael, Shestova, Olga, Patel, Prachi R., Kulikovskaya, Irina, Nazimuddin, Farzana, Bhoj, Vijay G., Orlando, Elena J., Fry, Terry J., Bitter, Hans, Maude, Shannon L., Levine, Bruce L., Nobles, Christopher L., Bushman, Frederic D., Young, Regina M., Scholler, John, Gill, Saar I., June, Carl H., Grupp, Stephan A., Lacey, Simon F., and Melenhorst, J. Joseph

Published
2018
Full Text
View/download PDF

17. Data from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Author

Wang, Enxiu, primary, Wang, Liang-Chuan, primary, Tsai, Ching-Yi, primary, Bhoj, Vijay, primary, Gershenson, Zack, primary, Moon, Edmund, primary, Newick, Kheng, primary, Sun, Jing, primary, Lo, Albert, primary, Baradet, Timothy, primary, Feldman, Michael D., primary, Barrett, David, primary, Puré, Ellen, primary, Albelda, Steven, primary, and Milone, Michael C., primary

Published
2023
Full Text
View/download PDF

18. Supplemental Figure 6 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Author

Wang, Enxiu, primary, Wang, Liang-Chuan, primary, Tsai, Ching-Yi, primary, Bhoj, Vijay, primary, Gershenson, Zack, primary, Moon, Edmund, primary, Newick, Kheng, primary, Sun, Jing, primary, Lo, Albert, primary, Baradet, Timothy, primary, Feldman, Michael D., primary, Barrett, David, primary, Puré, Ellen, primary, Albelda, Steven, primary, and Milone, Michael C., primary

Published
2023
Full Text
View/download PDF

19. Supplemental Figure 7 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Author

Wang, Enxiu, primary, Wang, Liang-Chuan, primary, Tsai, Ching-Yi, primary, Bhoj, Vijay, primary, Gershenson, Zack, primary, Moon, Edmund, primary, Newick, Kheng, primary, Sun, Jing, primary, Lo, Albert, primary, Baradet, Timothy, primary, Feldman, Michael D., primary, Barrett, David, primary, Puré, Ellen, primary, Albelda, Steven, primary, and Milone, Michael C., primary

Published
2023
Full Text
View/download PDF

20. Supplemental Figure 3 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Author

Wang, Enxiu, primary, Wang, Liang-Chuan, primary, Tsai, Ching-Yi, primary, Bhoj, Vijay, primary, Gershenson, Zack, primary, Moon, Edmund, primary, Newick, Kheng, primary, Sun, Jing, primary, Lo, Albert, primary, Baradet, Timothy, primary, Feldman, Michael D., primary, Barrett, David, primary, Puré, Ellen, primary, Albelda, Steven, primary, and Milone, Michael C., primary

Published
2023
Full Text
View/download PDF

21. Supplemental Figure 1 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Author

Wang, Enxiu, primary, Wang, Liang-Chuan, primary, Tsai, Ching-Yi, primary, Bhoj, Vijay, primary, Gershenson, Zack, primary, Moon, Edmund, primary, Newick, Kheng, primary, Sun, Jing, primary, Lo, Albert, primary, Baradet, Timothy, primary, Feldman, Michael D., primary, Barrett, David, primary, Puré, Ellen, primary, Albelda, Steven, primary, and Milone, Michael C., primary

Published
2023
Full Text
View/download PDF

22. Supplemental Figure 5 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Author

Wang, Enxiu, primary, Wang, Liang-Chuan, primary, Tsai, Ching-Yi, primary, Bhoj, Vijay, primary, Gershenson, Zack, primary, Moon, Edmund, primary, Newick, Kheng, primary, Sun, Jing, primary, Lo, Albert, primary, Baradet, Timothy, primary, Feldman, Michael D., primary, Barrett, David, primary, Puré, Ellen, primary, Albelda, Steven, primary, and Milone, Michael C., primary

Published
2023
Full Text
View/download PDF

23. Supplemental Figure 4 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Author

Wang, Enxiu, primary, Wang, Liang-Chuan, primary, Tsai, Ching-Yi, primary, Bhoj, Vijay, primary, Gershenson, Zack, primary, Moon, Edmund, primary, Newick, Kheng, primary, Sun, Jing, primary, Lo, Albert, primary, Baradet, Timothy, primary, Feldman, Michael D., primary, Barrett, David, primary, Puré, Ellen, primary, Albelda, Steven, primary, and Milone, Michael C., primary

Published
2023
Full Text
View/download PDF

24. Supplemental Figure Legends from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Author

Wang, Enxiu, primary, Wang, Liang-Chuan, primary, Tsai, Ching-Yi, primary, Bhoj, Vijay, primary, Gershenson, Zack, primary, Moon, Edmund, primary, Newick, Kheng, primary, Sun, Jing, primary, Lo, Albert, primary, Baradet, Timothy, primary, Feldman, Michael D., primary, Barrett, David, primary, Puré, Ellen, primary, Albelda, Steven, primary, and Milone, Michael C., primary

Published
2023
Full Text
View/download PDF

25. Supplemental Figure 2 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Author

Wang, Enxiu, primary, Wang, Liang-Chuan, primary, Tsai, Ching-Yi, primary, Bhoj, Vijay, primary, Gershenson, Zack, primary, Moon, Edmund, primary, Newick, Kheng, primary, Sun, Jing, primary, Lo, Albert, primary, Baradet, Timothy, primary, Feldman, Michael D., primary, Barrett, David, primary, Puré, Ellen, primary, Albelda, Steven, primary, and Milone, Michael C., primary

Published
2023
Full Text
View/download PDF

26. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

Author

Bhoj, Vijay G., Arhontoulis, Dimitrios, Wertheim, Gerald, Capobianchi, James, Callahan, Colleen A., Ellebrecht, Christoph T., Obstfeld, Amrom E., Lacey, Simon F., Melenhorst, Jan J., Nazimuddin, Farzana, Hwang, Wei-Ting, Maude, Shannon L., Wasik, Mariusz A., Bagg, Adam, Schuster, Stephen, Feldman, Michael D., Porter, David L., Grupp, Stephen A., June, Carl H., and Milone, Michael C.

Published
2016
Full Text
View/download PDF

28. Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders

Author

Baglaenko, Yuriy, primary, Wagner, Catriona, additional, Bhoj, Vijay G., additional, Brodin, Petter, additional, Gershwin, M. Eric, additional, Graham, Daniel, additional, Invernizzi, Pietro, additional, Kidd, Kenneth K., additional, Korsunsky, Ilya, additional, Levy, Michael, additional, Mammen, Andrew L., additional, Nizet, Victor, additional, Ramirez-Valle, Francisco, additional, Stites, Edward C., additional, Williams, Marc S., additional, Wilson, Michael, additional, Rose, Noel R., additional, Ladd, Virginia, additional, and Sirota, Marina, additional

Published
2023
Full Text
View/download PDF

31. 572 Gut microbiota tuning promotes tumor-associated antigen cross-presentation and enhances CAR T antitumor effects

Author

Facciabene, Andrea, primary, Uribe-Herranz, Mireia, additional, Beghi, Silvia, additional, Ruella, Marco, additional, Parvathaneni, Kalpana, additional, Ghilrardi, Guido, additional, Lee, Yung Gu, additional, Frey, Noelle, additional, Scholler, John, additional, Gabunia, Khatuna, additional, Specialist, Research, additional, Wu, Gary, additional, Chong, Elise, additional, Porter, David, additional, June, Carl, additional, Schuster, Stephen, additional, and Bhoj, Vijay, additional

Published
2022
Full Text
View/download PDF

32. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Author

Schuster, Stephen J., Svoboda, Jakub, Chong, Elise A., Nasta, Sunita D., Mato, Anthony R., Anak, Özlem, Brogdon, Jennifer L., Pruteanu-Malinici, Iulian, Bhoj, Vijay, Landsburg, Daniel, Wasik, Mariusz, Levine, Bruce L., Lacey, Simon F., Melenhorst, Jan J., Porter, David L., and June, Carl H.

Published
2017
Full Text
View/download PDF

34. Leveraging CAR T cells to Achieve Desensitization and Enable Transplantation

Author

Markmann, Caroline Anna, primary, Zheng, Zheng, additional, Yu, Ming, additional, Rostami, Susan, additional, Wang, Wei, additional, Ochoa, Trini, additional, Parvathaneni, Kalpana, additional, Xu, Xiaoming, additional, Scholler, John, additional, Zhang, Qian, additional, Posey, Avery, additional, Allman, David, additional, Milone, Michael, additional, Arruda, Valder, additional, Jones, Ben Samelson, additional, Naji, Ali, additional, and Bhoj, Vijay, additional

Published
2022
Full Text
View/download PDF

35. Alloantigen-specific Chimeric Antigen Receptor Regulatory T cell therapy in non-human primate islet transplantation

Author

Ellis, Gavin I., primary, Coker, Kimberly E., additional, Winn, Delaine W., additional, Deng, Mosha Z., additional, Shukla, Divanshu, additional, Bhoj, Vijay, additional, Milone, Michael C., additional, Wang, Wei, additional, Liu, Chengyang, additional, Naji, Ali, additional, Duran-Struuck, Raimon, additional, and Riley, James L., additional

Published
2022
Full Text
View/download PDF

36. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals

Author

Lederer, Katlyn, primary, Bettini, Emily, additional, Parvathaneni, Kalpana, additional, Painter, Mark M., additional, Agarwal, Divyansh, additional, Lundgreen, Kendall A., additional, Weirick, Madison, additional, Muralidharan, Kavitha, additional, Castaño, Diana, additional, Goel, Rishi R., additional, Xu, Xiaoming, additional, Drapeau, Elizabeth M., additional, Gouma, Sigrid, additional, Ort, Jordan T., additional, Awofolaju, Moses, additional, Greenplate, Allison R., additional, Le Coz, Carole, additional, Romberg, Neil, additional, Trofe-Clark, Jennifer, additional, Malat, Gregory, additional, Jones, Lisa, additional, Rosen, Mark, additional, Weiskopf, Daniela, additional, Sette, Alessandro, additional, Besharatian, Behdad, additional, Kaminiski, Mary, additional, Hensley, Scott E., additional, Bates, Paul, additional, Wherry, E. John, additional, Naji, Ali, additional, Bhoj, Vijay, additional, and Locci, Michela, additional

Published
2022
Full Text
View/download PDF

40. Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients

Author

Parvathaneni, Kalpana, primary, Toress-Rodriguez, Kyabeth, additional, Meng, Wenzhao, additional, Knox, James, additional, Xu, Xiaoming, additional, Weiskopf, Daniela, additional, Frey, Noelle V, additional, Luning-Prak, Eline, additional, Garfall, Alfred L, additional, Betts, Michael, additional, Hwang, Wei-Ting, additional, Porter, David L, additional, June, Carl H, additional, Naji, Ali, additional, and Bhoj, Vijay, additional

Published
2021
Full Text
View/download PDF

41. Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects

Author

Ruella, Marco, primary, Uribe-Herranz, Mireia, additional, Beghi, Silvia, additional, Parvathaneni, Kalpana, additional, Kostopoulos, Nektarios, additional, Ghilardi, Guido, additional, Amelsberg, Kimberly, additional, Lee, Yong Gu Gu, additional, Pajarillo, Raymone, additional, Frey, Noelle V, additional, Lacey, Simon F, additional, Gabunia, Khatuna, additional, Scholler, John, additional, Chong, Elise A, additional, June, Carl H, additional, Porter, David L., additional, Schuster, Stephen J., additional, Bhoj, Vijay, additional, and Facciabene, Andrea, additional

Published
2021
Full Text
View/download PDF

43. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals

Author

Lederer, Katlyn, primary, Parvathaneni, Kalpana, additional, Painter, Mark M., additional, Bettini, Emily, additional, Agarwal, Divyansh, additional, Lundgreen, Kendall A., additional, Weirick, Madison, additional, Goel, Rishi R., additional, Xu, Xiaoming, additional, Drapeau, Elizabeth M., additional, Gouma, Sigrid, additional, Greenplate, Allison R., additional, Coz, Carole Le, additional, Romberg, Neil, additional, Jones, Lisa, additional, Rosen, Mark, additional, Besharatian, Behdad, additional, Kaminiski, Mary, additional, Weiskopf, Daniela, additional, Sette, Alessandro, additional, Hensley, Scott E., additional, Bates, Paul, additional, Wherry, E. John, additional, Naji, Ali, additional, Bhoj, Vijay, additional, and Locci, Michela, additional

Published
2021
Full Text
View/download PDF

46. Ubiquitylation in innate and adaptive immunity

Author

Bhoj, Vijay G. and Chen, Zhijian J.

Subjects
Immune system -- Physiological aspects -- Research, Immune response -- Research -- Physiological aspects, Ubiquitin -- Physiological aspects -- Research, Environmental issues, Science and technology, Zoology and wildlife conservation, Physiological aspects, Research
Abstract

Protein ubiquitylation has emerged as a key mechanism that regulates immune responses. Much like phosphorylation, ubiquitylation is a reversible covalent modification that regulates the stability, activity and localization of target proteins. As such, ubiquitylation regulates the development of the immune system and many phases of the immune response, including its initiation, propagation and termination. Recent work has shown that several ubiquitin ligases help to prevent the immune system from attacking self tissues. The dysfunction of several ubiquitin ligases has been linked to autoimmune diseases., A safe and effective immune system must be capable of eradicating or containing a vast variety of invading microorganisms but must avoid attacking self tissues. To accomplish such a daunting [...]

Published
2009

48. Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4

Author

Bhoj, Vijay G., primary, Li, Lucy, additional, Parvathaneni, Kalpana, additional, Zhang, Zheng, additional, Kacir, Stephen, additional, Arhontoulis, Dimitrios, additional, Zhou, Kenneth, additional, McGettigan-Croce, Bevin, additional, Nunez-Cruz, Selene, additional, Gulendran, Gayathri, additional, Boesteanu, Alina C., additional, Johnson, Laura, additional, Feldman, Michael D., additional, Radaelli, Enrico, additional, Mansfield, Keith, additional, Nasrallah, MacLean, additional, Goydel, Rebecca S., additional, Peng, Haiyong, additional, Rader, Christoph, additional, Milone, Michael C., additional, and Siegel, Don L., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results